SCHEMBL658716

SCHEMBL658716

Clc1ccc(N2CCCNCC2)cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 6/20 0.85
HTR3A P46098 4/20 0.85
HTR3E A5X5Y0 3/20 0.85
HTR3B O95264 3/20 0.85
HTR3D Q70Z44 3/20 0.85
HTR3C Q8WXA8 3/20 0.85
SIGMAR1 Q99720 3/20 0.85
LTA4H P09960 2/20 0.69
CHRNB2 P17787 6/20 0.58
CHRNA4 P43681 6/20 0.58
CHRNA1 P02708 1/20 0.58
CHRNA7 P36544 1/20 0.58
HTR1A P08908 2/20 0.57
HTR7 P34969 2/20 0.57
HTR2B P41595 2/20 0.57
HTR6 P50406 2/20 0.57
HTR1D P28221 1/20 0.57
CETP P11597 2/20 0.55
CHRM2 P08172 1/20 0.55
CHRM4 P08173 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL894618 0.92 ADRB1 (1.00) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL219742 0.92 ADRB1 (1.00) ADRB1HTR3AHTR3EHTR3BHTR3D
Hydrochloric Acid SCHEMBL314621 0.90 ADRB1 (0.96) ADRB1HTR3AHTR3EHTR3BHTR3D
Hydrochloric Acid SCHEMBL708482 0.90 ADRB1 (0.96) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL7527162 0.86 ADRB1 (0.88) ADRB1HTR3AHTR3EHTR3BHTR3D
Phenylpiperazine SCHEMBL29089117 0.85 ADRB1 (0.85) ADRB1HTR3AHTR3EHTR3BHTR3D
Formaldehyde SCHEMBL27861281 0.85 ADRB1 (0.85) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL17276864 0.83 ADRB1 (0.68) ADRB1HTR3AHTR3EHTR3BHTR3D
Bicarbonate SCHEMBL11625611 0.83 ADRB1 (0.81) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL26635369 0.82 ADRB1 (0.57) ADRB1HTR3AHTR3EHTR3BHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663537-B2 Chemokine receptor antagonists and methods of use MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20160031908-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF KYOWA HAKKO KOGYO CO., LTD. (JP) 2016-02-04 US disclosed
US-20140371207-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-12-18 US disclosed
US-20140364420-A1 SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-12-11 US disclosed
US-20140364420-A1 SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-12-11 US disclosed
US-20140364420-A1 SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-12-11 US disclosed
US-8877745-B2 CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-04 US disclosed
US-8653096-B2 Chemokine receptor antagonists and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-02-18 US disclosed
US-8648197-B2 Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-02-11 US disclosed
US-8648197-B2 Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-02-11 US disclosed
US-20060172994-A1 Compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. 2006-08-03 US disclosed
WO-2006071958-A1 COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-07-06 WO disclosed
WO-2006071875-A1 COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-07-06 WO disclosed
US-20050070549-A1 Chemokine receptor antagonists and methods of use thereof KYOWA HAKKO KOGYO CO., LTD. (JP) 2005-03-31 US disclosed
EP-1448566-A2 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2004-08-25 EP disclosed
WO-2003045942-A2 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-06-05 WO disclosed
US-20030045516-A1 Chemokine receptor antagonists and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2003-03-06 US disclosed
US-6509346-B2 Antiinflammatory agents MILLENNIUM PHARMACEUTICALS, INC. 2003-01-21 US disclosed
US-20020169155-A1 A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation MILLENNIUM PHARMACEUTICALS, INC. 2002-11-14 US disclosed
US-20020119973-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS, INC. 2002-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119973-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR CCL11, ACKR3, CXCR4 ADRB1 1142/4885HTR3A 2004/4885HTR3E 2299/4885
US-20060172994-A1 Compounds useful as chemokine receptor antagonists ACKR3, CCR5, CXCR2 ADRB1 743/4885HTR3A 1810/4885HTR3E 1840/4885
US-20020169155-A1 A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation NFATC1, ELANE, NCF1 ADRB1 4056/4885HTR3A 4388/4885HTR3E 4604/4885
US-20140364420-A1 SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS ACKR3, CCR5, CCR2 ADRB1 894/4885HTR3A 1525/4885HTR3E 2071/4885
US-20160031908-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF ACKR3, CCR2, CXCR2 ADRB1 496/4885HTR3A 1369/4885HTR3E 1505/4885
US-20050070549-A1 Chemokine receptor antagonists and methods of use thereof ACKR3, CXCR2, CCL11 ADRB1 295/4885HTR3A 1649/4885HTR3E 2109/4885
US-20140371207-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF ACKR3, CCR2, CXCR2 ADRB1 496/4885HTR3A 1369/4885HTR3E 1505/4885
US-20030045516-A1 Chemokine receptor antagonists and methods of use therefor CCL11, ACKR3, CXCR4 ADRB1 1101/4885HTR3A 2015/4885HTR3E 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.